Interactive biomembranes for wound management – exploiting the unique wound healing and antimicrobial properties of human collagen VI

Información del proyecto

WOUNDCOM

Identificador del acuerdo de subvención: 827599

DOI

10.3030/827599

Proyecto cerrado

Fecha de la firma de la CE 13 Julio 2018

Fecha de inicio 1 Agosto 2018

Fecha de finalización 31 Enero 2019

Financiado con arreglo a

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

COLZYX AB
Sweden

Periodic Reporting for period 1 - WOUNDCOM (Interactive biomembranes for wound management – exploiting the unique wound healing and antimicrobial properties of human collagen VI)

Período documentado: 2018-08-01 hasta 2019-01-31

Resumen del contexto y de los objetivos generales del proyecto

The available wound care options can manipulate one or multiple aspects of the wound environment, but cannot form an antibacterial barrier and facilitate healing to a satisfactory level at the same time. Colzyx aims to address this challenge and unmet need by developing its bioactive wound dressing that will make use of the newly discovered wound healing and antimicrobial properties of human collagen VI and parts thereof. WOUNDCOM is to be used in all post-surgery treatment mediating rapid wound healing and antimicrobial effect and, above all, in the treatment of chronic wounds, such as diabetic foot and venous leg ulcers.

The overall objectives of this project were to develop and optimise business plan that will guide exploitation and commercialisation of Colzyx’s novel dressing that 1) promotes rapid wound closure, 2) promotes normal wound healing, 3) reduces scar complications and tissue contractions, and 4) reduced the risk of bacterial infection. Moreover, our goal was to define success factors, revenue goals and assess WOUNDCOM’s health economic potential.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

Colzyx used Strategic Business Planning Methodology to perform the feasibility study, which will then guide the overall business development strategy. It provided a valuable understanding of the current trends and opportunities on the wound management market, targeted users, competitors and potential partnerships. A work plan for the clinical study to evaluate WOUNDCOM’s performance, safety and tolerability in patients with chronic wounds was also developed as part of this project.

The feasibility study has confirmed that there is a clear business opportunity to exploit the global wound care market and to deliver the first-in-class bioactive product for effective wound care management.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

This feasibility study has confirmed the innovative character of Colzyx’s approach. The novelty of our wound dressing goes beyond the state of the art in wound care. Basing on a ground-breaking discovery of wound healing and antimicrobial properties of human collagen VI and parts thereof, Colzyx has developed the product that has the potential to revolutionise the wound management market and create a new category of interactive biomembranes. Chronic wounds are a global problem as they decrease patients’ quality of life and generate high medical costs. Novel wound care products addressing both: rapid wound closure and combat of infections are urgently needed and Colzyx aims to address unmet challenge with its product.

WOUNDCOM product for wound management: the Effector coupled to the Carrier